Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report

Abstract Background Concomitant multiple myeloma (MM) and other primary malignancies is rare. Therefore, the treatment outcomes of patients with these conditions have not been well discussed. Lenalidomide is an oral thalidomide analog drug used for MM. Recently, the antitumor effect of lenalidomide...

Full description

Bibliographic Details
Main Authors: Koki Tamai, Hajime Hirose, Yo Akazawa, Yukihiro Yoshikawa, Masatoshi Nomura, Hiroshi Takeyama, Masahiro Tokunaga, Mitsuyoshi Tei, Shu Okamura, Yusuke Akamaru
Format: Article
Language:English
Published: SpringerOpen 2024-02-01
Series:Surgical Case Reports
Subjects:
Lenalidomide
Mucinous adenocarcinoma
Peritoneal dissemination
Multiple myeloma
Online Access:https://doi.org/10.1186/s40792-024-01838-5

Internet

https://doi.org/10.1186/s40792-024-01838-5

Similar Items